Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Multiple endocrine neoplasia type 1 (MEN1) is defined in the packet as an autosomal dominant tumor predisposition syndrome caused by pathogenic variants in the MEN1 gene. It is characterized by an increased risk of tumors of the parathyroid glands, the pituitary gland and foregut neuroendocrine tumors, most commonly of the pancreatic islet cells. GeneReviews describes the condition as characterized by varying combinations of more than 20 endocrine and non-endocrine tumors. Orphanet-derived prevalence in the packet is categorized as uncommon, at 1 to 9 in 100,000, and GeneReviews gives a prevalence of between 1 in 10,000 and 1 in 100,000 individuals, with geographic clustering from a founder effect reported. The packet records Wermer syndrome among its synonyms and lists the endocrine system as the affected organ system.
The packet phenotype data list pituitary adenoma and pituitary prolactin cell adenoma as frequent features (30-79%), and carcinoid tumor, adrenocortical adenoma and insulinoma as occasional features (5-29%). GeneReviews describes primary hyperparathyroidism as the most common MEN1-associated endocrinopathy and as the first clinical feature in 90% of affected individuals, often mild, with onset typically between ages 20 and 25 years, and states that hypercalcemia can be expected in all affected individuals by age 50 years. Its tumor table reports anterior pituitary tumors in roughly 30% to 40% of individuals, with prolactinoma the most frequent subtype at 60% of these, followed by growth hormone-secreting tumors at 25%. Well-differentiated endocrine tumors of the gastroenteropancreatic tract include gastrinoma (40%), insulinoma (10%), glucagonoma (3%), VIPoma (3%) and somatostatinoma (1%), with nonfunctioning tumors at 55%. Thymic carcinoids (3% to 8%), bronchial carcinoids (4.7% to 6.6%) and type II gastric enterochromaffin-like carcinoids (10%) are also listed, as are cortisol-secreting adrenocortical tumors (40%) and pheochromocytoma (1%). GeneReviews notes that MEN1-associated tumors are often clinically distinct from sporadically occurring tumors of the same tissue type.
MEN1 is caused by pathogenic variants in the MEN1 gene, located on chromosome 11; ClinGen classifies the gene-disease validity as definitive. The packet records autosomal dominant inheritance. GeneReviews states that approximately 90% of individuals diagnosed with MEN1 have an affected parent and approximately 10% have the disorder as the result of a de novo MEN1 pathogenic variant that occurred in early embryogenesis. It also describes the possibility of parental germline or somatic and germline mosaicism when a variant is not found in either parent, and notes that an apparently negative family history may reflect unrecognized disease, early parental death or late onset. On penetrance, GeneReviews reports that age-related penetrance for all clinical features surpasses 50% by age 20 years and 95% by age 40 years. It reports that no direct genotype-phenotype correlations have been identified, although one reported variant, p.Arg460Ter (the Burin variant), identified in kindreds from Newfoundland and Mauritius, was associated with a higher than average prevalence of prolactinoma and a lower than average prevalence of gastrinoma. GeneReviews also associates smoking with a higher risk of carcinoid tumors in individuals with MEN1.
GeneReviews states that MEN1 is suspected in individuals with endocrine tumors, although non-endocrine tumors may appear before hormone-secreting endocrine tumors, and that no clinical criteria or definition can capture all affected individuals. Parathyroid tumors manifest as hypercalcemia from primary hyperparathyroidism due to parathyroid hormone overproduction, usually from multiglandular disease. Prolactinomas manifest as oligomenorrhea or amenorrhea and galactorrhea in females and sexual dysfunction and, more rarely, gynecomastia in males; growth hormone-secreting adenomas cause gigantism in children and acromegaly in adults; ACTH-secreting adenomas are mostly associated with Cushing disease; and nonfunctioning adenomas may present as enlarging tumors with visual disturbance or hypopituitarism. For gastroenteropancreatic tumors, presentations listed from most to least frequent are Zollinger-Ellison syndrome, hypoglycemia from insulinoma, the glucagonoma syndrome and the VIPoma syndrome. GeneReviews identifies MRI as the imaging test of choice for pituitary tumors and endoscopic ultrasound as the most sensitive procedure for small pancreatic endocrine tumors, and notes that nonfunctioning pancreatic endocrine tumors are the most frequently seen tumors. Its evaluation and surveillance tables cover calcium and parathyroid hormone, pituitary hormones with head MRI, pancreatic hormones, gastrin, chest and abdominal imaging and skin examination, with age thresholds that differ by tumor type, and list genetic counseling by genetics professionals. Newborn-screening information is not certified in this packet.
No FDA-approved treatment for MEN1 is identified in this packet. GeneReviews management content describes multidisciplinary, tumor-specific care. For primary hyperparathyroidism, GeneReviews describes parathyroidectomy as the treatment of choice, with debate over subtotal versus total parathyroidectomy and over timing. It reports persistent or recurrent hypercalcemia within ten to 12 years after subtotal parathyroidectomy in 40% to 60% of affected individuals, and hypocalcemia requiring long-term therapy in 10% to 30%. Total parathyroidectomy with forearm autotransplantation is described, with recurrent hypercalcemia in more than 50% of those with autotransplanted tissue. GeneReviews states that parathyroidectomy is considered mandatory in individuals with Zollinger-Ellison syndrome and that individuals with asymptomatic hypercalcemia can usually defer surgery in favor of regular assessment. It also describes calcimimetic therapy as used for those who are not surgical candidates or who have postsurgical recurrence. Therapies under investigation, per GeneReviews, include anti-VEGF-A antibody blockade studied in an animal model of pituitary adenoma and somatostatin analogs for gastroenteropancreatic tumors, supported by a study reporting a progression-free survival effect in individuals with MEN1. Management content for other tumor types is not included in the packet fields summarized here.
15 trials found
Natural history information in GeneReviews describes primary hyperparathyroidism as the first feature in most affected individuals and age-related penetrance rising above 95% by age 40 years. GeneReviews states that surveillance can detect disease about ten years before symptoms develop and describes early detection of potentially malignant neuroendocrine tumors as expected to reduce morbidity and mortality. One reported study cited in GeneReviews found a twofold higher risk of death in individuals with a heterozygous MEN1 pathogenic variant affecting the JunD interacting domain of menin. The packet does not certify life expectancy or survival figures.
Several certified active trial records are present on ClinicalTrials.gov for multiple endocrine neoplasia type 1. They include a Phase 2 record sponsored by M.D. Anderson Cancer Center (NCT03950609, active, not recruiting), recruiting records sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NCT04969926), Sanford Health (NCT01793168) and St. Jude Children's Research Hospital (NCT03050268), and a not-yet-recruiting record sponsored by F.I.R.M.O. Fondazione Italiana Ricerca sulle Malattie dell'Osso (NCT06790251). Trial titles alone do not establish what an intervention involves or whether it is effective.
Data assembled from 9 of 12 sources · Last updated Nov 17, 2026, 10:59 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning multiple endocrine neoplasia type 1
Updated Aug 23, 2026
A recent case-based management review highlights how disease progression alters operative thresholds in multiple endocrine neoplasia type 1 (MEN1). This research provides insights that could influence clinical decision-making for patients with MEN1.
A recent study published in PubMed explores the association between functioning gonadotroph macroadenoma and multiple endocrine neoplasia type 1. This research contributes to the understanding of the genetic and clinical implications of these conditions.
A new study explores bilateral macronodular adrenal disease in patients with multiple endocrine neoplasia type 1. This research adds to the understanding of the disease's impact on adrenal function.